問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Search Result

Search Result

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

E-DA Hospital

Recruiting

List

87Cases

2016-11-01 - 2019-11-30

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
9Sites

Recruiting8Sites

2021-01-22 - 2023-03-23

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
10Sites

Not yet recruiting2Sites

Recruiting8Sites

2024-08-01 - 2025-12-31

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting4Sites

2016-02-22 - 2022-12-22

Phase II

A phase II, multicenter, four-cohort study of oral cMET inhibitor INC280 in adult patients with EGFR wild-type (wt), advanced non-small cell lung cancer (NSCLC) who have received one or two prior lines of systemic therapy for advanced/metastatic disease

  • Condition/Disease

    Non-small Cell Lung Cancer

  • Test Drug

    INC280

Participate Sites
6Sites

Recruiting5Sites

夏德椿
China Medical University Hospital-Taipei

未分科

張文震
Linkou Chang Gung Medical Foundation

Division of Hematology & Oncology

2018-10-24 - 2024-03-31

Phase III

SELECT - Semaglutide effects on cardiovascular outcomes in people with overweight or obesity

  • Condition/Disease

    Obesity

  • Test Drug

    Semaglutide B 3.0 mg/mL PDS290 or Semaglutide placebo

Participate Sites
6Sites

Recruiting4Sites

Terminated2Sites

謝宜璋
Linkou Chang Gung Medical Foundation

Division of Cardiovascular Diseases

2020-08-01 - 2021-08-19

Phase III

A Phase III, Prospective, Multi-center, Double-blind, Randomized, Parallel-Group Study to Compare the Efficacy and Safety of Pitavastatin 2 mg/ Ezetimibe 10 mg with Pitavastatin and Ezetimibe in Patients with Primary Hypercholesterolemia or Mixed Dyslipidemia

  • Condition/Disease

    Primary Hypercholesterolemia/Mixed Dyslipidemias

  • Test Drug

    1PC111

Participate Sites
23Sites

Not yet recruiting4Sites

Recruiting19Sites

2023-02-15 - 2025-06-30

Phase I

A Phase 1a/1b Study to Evaluate the Safety and Tolerability of Repeated Doses of Nonreplicating Arenavirus Vector Therapeutic Vaccines GS-2829 and GS-6779 in Healthy Participants and Participants With Chronic Hepatitis B (CHB)

  • Condition/Disease

    Chronic Hepatitis B

  • Test Drug

    GS-2829GS-6779

Participate Sites
10Sites

Recruiting10Sites

1 5 6 7 8 9
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB